Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
alison.lawrie@ndm.ox.ac.uk

Research groups

Alison Lawrie

Senior Vaccine Development Co-ordinator & Head of Regulatory Affairs

Recent publications

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Journal article

Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Journal article

Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Journal article

Silk SE. et al, (2023), Med, 4, 668 - 686.e7
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Journal article

Minassian AM. et al, (2021), Med, 2, 701 - 719.e19
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Journal article

Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262

More publications